Hydromorphone tablets are intended to relieve moderate to severe acute pain in patients when opioid use is necessary and appropriate.
The tablets are a generic version of Stamford, Conn.-based Purdue Pharma’s Dilaudid tablets.
The India-based drug company’s new tablets represent the 12th approved treatment developed by its Dayton, N.J.-based subsidiary Aurolife.
More articles on the drug market:
Drug shortages force workarounds in Conn. hospitals
4 reasons adults need vaccines just as much as kids
Drugmakers have firm grasp on drug pricing power
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
